# Allurion Technologies, Inc.: financial statements, quarterly

ALUR · OTC · CIK 1964979 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alur.md) · [Financials](/companies/alur/financials.md) · [Filings](/companies/alur/filings.md) · [Insiders](/companies/alur/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alur/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.0](/filings/0000950170-25-112000.md) | [18.2](/filings/0000950170-25-112011.md) | [8.2 d](/filings/0000950170-25-111978.md) | [9.4](/filings/0000950170-25-111984.md) | [11.8](/filings/0000950170-25-112000.md) | [5.4](/filings/0001193125-25-284630.md) | [5.6 d](/filings/0001193125-26-130483.md) | [5.6](/filings/0001193125-26-226960.md) | [3.4](/filings/0000950170-25-110188.md) | [2.7](/filings/0001193125-25-284630.md) | [3.6 d](/filings/0001193125-26-130483.md) | [2.9](/filings/0001193125-26-226960.md) |
| Cost of revenue | $m | [3.0](/filings/0000950170-25-112000.md) | [4.2](/filings/0000950170-25-112011.md) | [1.8 d](/filings/0000950170-25-111978.md) | [2.5](/filings/0000950170-25-111984.md) | [2.8](/filings/0000950170-25-112000.md) | [2.3](/filings/0001193125-25-284630.md) | [3.1 d](/filings/0001193125-26-130483.md) | [1.4](/filings/0001193125-26-226960.md) | [0.9](/filings/0000950170-25-110188.md) | [1.4](/filings/0001193125-25-284630.md) | [2.0 d](/filings/0001193125-26-130483.md) | [1.7](/filings/0001193125-26-226960.md) |
| Gross profit | $m | [10.0](/filings/0000950170-25-112000.md) | [14.0](/filings/0000950170-25-112011.md) | [6.4 d](/filings/0000950170-25-111978.md) | [6.9](/filings/0000950170-25-111984.md) | [9.0](/filings/0000950170-25-112000.md) | [3.1](/filings/0001193125-25-284630.md) | [2.5 d](/filings/0001193125-26-130483.md) | [4.2](/filings/0001193125-26-226960.md) | [2.5](/filings/0000950170-25-110188.md) | [1.3](/filings/0001193125-25-284630.md) | [1.6 d](/filings/0001193125-26-130483.md) | [1.2](/filings/0001193125-26-226960.md) |
| Research and development | $m | [6.6](/filings/0000950170-25-112000.md) | [7.2](/filings/0000950170-25-112011.md) | [6.1 d](/filings/0000950170-25-111978.md) | [5.7](/filings/0000950170-25-111984.md) | [4.3](/filings/0000950170-25-112000.md) | [3.2](/filings/0001193125-25-284630.md) | [4.1 d](/filings/0001193125-26-130483.md) | [2.6](/filings/0001193125-26-226960.md) | [1.8](/filings/0000950170-25-110188.md) | [2.0](/filings/0001193125-25-284630.md) | [1.1 d](/filings/0001193125-26-130483.md) | [0.9](/filings/0001193125-26-226960.md) |
| Operating income | $m | [(13.3)](/filings/0000950170-25-112000.md) | [(26.2)](/filings/0000950170-25-112011.md) | [(25.7) d](/filings/0000950170-25-111978.md) | [(11.4)](/filings/0000950170-25-111984.md) | [(9.3)](/filings/0000950170-25-112000.md) | [(12.3)](/filings/0001193125-25-284630.md) | [(17.1) d](/filings/0001193125-26-130483.md) | [(7.3)](/filings/0001193125-26-226960.md) | [(7.0)](/filings/0000950170-25-110188.md) | [(9.6)](/filings/0001193125-25-284630.md) | [(6.3) d](/filings/0001193125-26-130483.md) | [(3.7)](/filings/0001193125-26-226960.md) |
| Interest expense | $m | [2.5](/filings/0000950170-24-097089.md) | [2.6](/filings/0000950170-23-063858.md) | [3.2 d](/filings/0000950170-24-036478.md) | [1.9](/filings/0000950170-24-059687.md) | [0.3](/filings/0000950170-24-097089.md) | [0.0](/filings/0001193125-25-284630.md) | [0.0 d](/filings/0001193125-26-130483.md) | not reported | [0.0](/filings/0000950170-25-110188.md) | [0.0](/filings/0001193125-25-284630.md) | [0.0 d](/filings/0001193125-26-130483.md) | not reported |
| Income tax | $m | [0.0](/filings/0000950170-25-112000.md) | [0.0](/filings/0000950170-25-112011.md) | [0.2 d](/filings/0000950170-25-111978.md) | [0.1](/filings/0000950170-25-111984.md) | [0.1](/filings/0000950170-25-112000.md) | [0.1](/filings/0001193125-25-284630.md) | [0.5 d](/filings/0001193125-26-130483.md) | [0.1](/filings/0001193125-26-226960.md) | [0.0](/filings/0000950170-25-110188.md) | [0.0](/filings/0001193125-25-284630.md) | [(0.1) d](/filings/0001193125-26-130483.md) | [0.0](/filings/0001193125-26-226960.md) |
| Net income | $m | [(22.0)](/filings/0000950170-25-112011.md) | [(21.6)](/filings/0000950170-25-112011.md) | [(21.4) d](/filings/0000950170-25-111978.md) | [2.0](/filings/0001193125-25-284630.md) | [(8.3)](/filings/0001193125-25-284630.md) | [8.7](/filings/0001193125-25-284630.md) | [(9.6) d](/filings/0001193125-26-130483.md) | [(1.5)](/filings/0001193125-26-226960.md) | [(9.3)](/filings/0001193125-25-284630.md) | [(11.9)](/filings/0001193125-25-284630.md) | [(6.0) d](/filings/0001193125-26-130483.md) | [(6.1)](/filings/0001193125-26-226960.md) |
| Diluted EPS | $ per share | [(20.95)](/filings/0000950170-25-112000.md) | [(13.56)](/filings/0000950170-25-112011.md) | not reported | [0.96](/filings/0000950170-25-111984.md) | [(4.34)](/filings/0000950170-25-112000.md) | [3.40](/filings/0001193125-25-284630.md) | not reported | [(0.31)](/filings/0001193125-26-226960.md) | [(1.28)](/filings/0000950170-25-110188.md) | [(1.53)](/filings/0001193125-25-284630.md) | not reported | [(0.46)](/filings/0001193125-26-226960.md) |
| Basic EPS | $ per share | [(20.95)](/filings/0000950170-25-112000.md) | [(13.56)](/filings/0000950170-25-112011.md) | not reported | [1.04](/filings/0000950170-25-111984.md) | [(4.34)](/filings/0000950170-25-112000.md) | [3.41](/filings/0001193125-25-284630.md) | not reported | [(0.31)](/filings/0001193125-26-226960.md) | [(1.28)](/filings/0000950170-25-110188.md) | [(1.53)](/filings/0001193125-25-284630.md) | not reported | [(0.46)](/filings/0001193125-26-226960.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.7](/filings/0000950170-23-054423.md) | [79.9](/filings/0000950170-23-063858.md) | [38.0](/filings/0000950170-25-112011.md) | [29.7](/filings/0000950170-25-111984.md) | [19.3](/filings/0000950170-25-112000.md) | [28.7](/filings/0000950170-25-112011.md) | [15.4](/filings/0001193125-26-130483.md) | [20.4](/filings/0000950170-25-110164.md) | [12.7](/filings/0000950170-25-110188.md) | [6.1](/filings/0001193125-25-284630.md) | [5.4](/filings/0001193125-26-226960.md) | [5.1](/filings/0001193125-26-226960.md) |
| Current assets | $m | [37.1](/filings/0000950170-23-054423.md) | [114](/filings/0000950170-23-063858.md) | [64.8](/filings/0000950170-25-112011.md) | [53.6](/filings/0000950170-25-111984.md) | [40.3](/filings/0000950170-25-112000.md) | [44.8](/filings/0000950170-25-112011.md) | [27.2](/filings/0001193125-26-130483.md) | [33.2](/filings/0000950170-25-110164.md) | [23.5](/filings/0000950170-25-110188.md) | [14.6](/filings/0001193125-25-284630.md) | [12.8](/filings/0001193125-26-226960.md) | [11.3](/filings/0001193125-26-226960.md) |
| Total assets | $m | [52.2](/filings/0000950170-23-054423.md) | [121](/filings/0000950170-23-063858.md) | [71.7](/filings/0000950170-25-112011.md) | [60.0](/filings/0000950170-25-111984.md) | [46.6](/filings/0000950170-25-112000.md) | [50.7](/filings/0000950170-25-112011.md) | [32.8](/filings/0001193125-26-130483.md) | [38.4](/filings/0000950170-25-110164.md) | [28.2](/filings/0000950170-25-110188.md) | [18.1](/filings/0001193125-25-284630.md) | [15.8](/filings/0001193125-26-226960.md) | [14.0](/filings/0001193125-26-226960.md) |
| Current liabilities | $m | [89.9](/filings/0000950170-23-054423.md) | [87.2](/filings/0000950170-23-063858.md) | [65.4](/filings/0000950170-25-112011.md) | [66.2](/filings/0000950170-25-111984.md) | [23.6](/filings/0000950170-25-112000.md) | [19.2](/filings/0000950170-25-112011.md) | [18.9](/filings/0001193125-26-130483.md) | [15.9](/filings/0000950170-25-110164.md) | [11.6](/filings/0000950170-25-110188.md) | [11.6](/filings/0001193125-25-284630.md) | [38.4](/filings/0001193125-26-226960.md) | [37.3](/filings/0001193125-26-226960.md) |
| Total liabilities | $m | [123](/filings/0000950170-23-054423.md) | [173](/filings/0000950170-23-063858.md) | [143](/filings/0000950170-25-112011.md) | [126](/filings/0000950170-25-111984.md) | [117](/filings/0000950170-25-112000.md) | [115](/filings/0000950170-25-112011.md) | [111](/filings/0001193125-26-130483.md) | [108](/filings/0000950170-25-110164.md) | [92.1](/filings/0000950170-25-110188.md) | [101](/filings/0001193125-25-284630.md) | [93.0](/filings/0001193125-26-226960.md) | [91.9](/filings/0001193125-26-226960.md) |
| Long-term debt | $m | [19.9](/filings/0000950170-23-054423.md) | not reported | not reported | not reported | [41.0](/filings/0000950170-25-112000.md) | [36.1](/filings/0000950170-25-112011.md) | [35.7](/filings/0000950170-25-110188.md) | [31.0](/filings/0000950170-25-110164.md) | [28.8](/filings/0000950170-25-110188.md) | not reported | [0.0](/filings/0001193125-26-226960.md) | [0.0](/filings/0001193125-26-226960.md) |
| Current portion of debt | $m | [53.7](/filings/0000950170-23-054423.md) | [57.7](/filings/0000950170-23-063858.md) | [38.6](/filings/0000950170-25-112011.md) | [39.0](/filings/0000950170-25-111984.md) | not reported | not reported | [35.7](/filings/0000950170-25-072662.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(71.2)](/filings/0000950170-25-112011.md) | [(52.8)](/filings/0000950170-25-112011.md) | [(71.3)](/filings/0001193125-26-130483.md) | [(66.2)](/filings/0001193125-25-284630.md) | [(70.6)](/filings/0001193125-25-284630.md) | [(64.8)](/filings/0001193125-25-284630.md) | [(78.0)](/filings/0001193125-26-226960.md) | [(69.8)](/filings/0001193125-26-226960.md) | [(64.0)](/filings/0001193125-25-284630.md) | [(82.9)](/filings/0001193125-25-284630.md) | [(77.2)](/filings/0001193125-26-226960.md) | [(77.9)](/filings/0001193125-26-226960.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.7) d](/filings/0000950170-25-112000.md) | [(23.1) d](/filings/0000950170-25-112011.md) | [(20.9) d](/filings/0000950170-25-111978.md) | [(8.6)](/filings/0000950170-25-111984.md) | [(8.9) d](/filings/0000950170-25-112000.md) | [(11.5) d](/filings/0001193125-25-284630.md) | [(13.3) d](/filings/0001193125-26-130483.md) | [(9.5)](/filings/0001193125-26-226960.md) | [(7.6) d](/filings/0000950170-25-110188.md) | [(6.5) d](/filings/0001193125-25-284630.md) | [(5.3) d](/filings/0001193125-26-130483.md) | [(3.2)](/filings/0001193125-26-226960.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-25-112000.md) | [0.8 d](/filings/0000950170-25-112011.md) | [0.4 d](/filings/0000950170-25-111978.md) | [0.1](/filings/0000950170-25-111984.md) | [0.4 d](/filings/0000950170-25-112000.md) | [0.1 d](/filings/0001193125-25-284630.md) | [0.0 d](/filings/0001193125-26-130483.md) | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-06-30) | period not labelled (2022-09-30) | period not labelled (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.5](/filings/0000950170-23-054423.md) | [26.9](/filings/0000950170-23-063858.md) | [1.1](/filings/0000950170-25-111984.md) | [1.1](/filings/0000950170-25-112000.md) | [1.6](/filings/0000950170-25-112011.md) | [2.0](/filings/0000950170-25-111984.md) | [1.9](/filings/0000950170-25-112000.md) | [2.6](/filings/0001193125-25-284630.md) | [4.8](/filings/0001193125-26-226960.md) | [7.3](/filings/0000950170-25-110188.md) | [7.8](/filings/0001193125-25-284630.md) | [13.4](/filings/0001193125-26-226960.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 15,006,253 at 2026-05-12, from the cover of the [10-Q filed 2026-05-15](/filings/0001193125-26-226960.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.